Physician profile
Scott A Trail
NPI 1437110798
$7,761.42
in general payments reported to CMS, 2019-2025
17 companies · $295 in 2025
The $295 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,226 · 2020: $122 · 2021: $819 · 2022: $323 · 2023: $502 · 2024: $475 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $5,280.10 | 2019-2025 | Qelbree, Qelbree |
| Corium, LLC | $612.55 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $336.20 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $310.97 | 2019-2025 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $261.07 | 2019-2021 | |
| Neos Therapeutics, Lp | $242.14 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $232.16 | 2019-2022 | |
| Abbvie INC. | $151.74 | 2023-2024 | Vraylar |
| Shire North American Group INC | $85.69 | 2019 | |
| Noven Therapeutics, LLC | $58.85 | 2024-2025 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $52.33 | 2019-2025 | Relexxii |
| Adlon Therapeutics L.P. | $41.30 | 2020-2021 | |
| Rhodes Pharmaceuticals L.P. | $25.73 | 2019 | |
| Collegium Pharmaceutical, INC. | $20.49 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $18.20 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $16.93 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Trail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.